Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
- Authors
- Park S.W.; Um S.H.; Lee H.A.; Kim S.H.; Sim Y.; Yim S.Y.; Seo Y.S.; Ryu H.S.
- Issue Date
- Jun-2016
- Keywords
- Autoimmune hepatitis; Azathioprine; Mycophenolate mofetil
- Citation
- Clinical and molecular hepatology, v.22, no.2, pp 281 - 285
- Pages
- 5
- Indexed
- SCOPUS
KCI
- Journal Title
- Clinical and molecular hepatology
- Volume
- 22
- Number
- 2
- Start Page
- 281
- End Page
- 285
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7086
- DOI
- 10.3350/cmh.2015.0040
- ISSN
- 2287-2728
2287-285X
- Abstract
- Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.